{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T09:53:58Z","timestamp":1791021238341,"version":"4.1.0"},"reference-count":94,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","award":["R01 DK128552"],"award-info":[{"award-number":["R01 DK128552"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Best Practice & Research Clinical Rheumatology"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.berh.2026.102203","type":"journal-article","created":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T03:56:58Z","timestamp":1790913418000},"page":"102203","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Future directions of osteoanabolic therapies in osteoporosis: Integrating current anabolic agents and emerging senescence-targeted strategies"],"prefix":"10.1016","author":[{"given":"Hannah W.","family":"Brooks","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas C.","family":"Cusick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuang","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3179-6414","authenticated-orcid":false,"given":"Joshua N.","family":"Farr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.berh.2026.102203_bib1","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1210\/endrev\/bnag006","article-title":"Management of postmenopausal osteoporosis","volume":"47","author":"Reid","year":"2026","journal-title":"Endocr Rev"},{"issue":"10329","key":"10.1016\/j.berh.2026.102203_bib2","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1016\/S0140-6736(21)02646-5","article-title":"Drug therapy for osteoporosis in older adults","volume":"399","author":"Reid","year":"2022","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.berh.2026.102203_bib3","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1016\/j.mayocp.2022.03.011","article-title":"Skeletal aging","volume":"97","author":"Sfeir","year":"2022","journal-title":"Mayo Clin Proc"},{"issue":"4","key":"10.1016\/j.berh.2026.102203_bib4","doi-asserted-by":"crossref","DOI":"10.1002\/jbm4.10488","article-title":"Bone aging, cellular senescence, and osteoporosis","volume":"5","author":"Pignolo","year":"2021","journal-title":"JBMR Plus"},{"issue":"10","key":"10.1016\/j.berh.2026.102203_bib5","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1007\/s00198-021-05900-y","article-title":"The clinician's guide to prevention and treatment of osteoporosis","volume":"33","author":"LeBoff","year":"2022","journal-title":"Osteoporos Int"},{"issue":"1","key":"10.1016\/j.berh.2026.102203_bib6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00198-019-05176-3","article-title":"Algorithm for the management of patients at low, high and very high risk of osteoporotic fractures","volume":"31","author":"Kanis","year":"2020","journal-title":"Osteoporos Int"},{"issue":"3","key":"10.1016\/j.berh.2026.102203_bib7","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1056\/NEJMcp1513724","article-title":"Clinical practice. Postmenopausal osteoporosis","volume":"374","author":"Black","year":"2016","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.berh.2026.102203_bib8","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1007\/s00198-016-3868-0","article-title":"Imminent risk of fracture after fracture","volume":"28","author":"Johansson","year":"2017","journal-title":"Osteoporos Int"},{"issue":"21","key":"10.1016\/j.berh.2026.102203_bib9","doi-asserted-by":"crossref","first-page":"2250","DOI":"10.1056\/NEJMra053077","article-title":"Bone quality--the material and structural basis of bone strength and fragility","volume":"354","author":"Seeman","year":"2006","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.berh.2026.102203_bib10","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1093\/jbmr\/zjae119","article-title":"Goal-directed osteoporosis treatment: ASBMR\/BHOF task force position statement 2024","volume":"39","author":"Cosman","year":"2024","journal-title":"J Bone Miner Res"},{"issue":"4","key":"10.1016\/j.berh.2026.102203_bib11","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1007\/s40520-022-02100-4","article-title":"Management of patients at very high risk of osteoporotic fractures through sequential treatments","volume":"34","author":"Curtis","year":"2022","journal-title":"Aging Clin Exp Res"},{"issue":"9041","key":"10.1016\/j.berh.2026.102203_bib12","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1016\/S0140-6736(96)07088-2","article-title":"Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture intervention trial research group","volume":"348","author":"Black","year":"1996","journal-title":"Lancet"},{"issue":"18","key":"10.1016\/j.berh.2026.102203_bib13","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa067312","article-title":"Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis","volume":"356","author":"Black","year":"2007","journal-title":"N Engl J Med"},{"issue":"25","key":"10.1016\/j.berh.2026.102203_bib14","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1056\/NEJMoa1808082","article-title":"Fracture prevention with zoledronate in older women with osteopenia","volume":"379","author":"Reid","year":"2018","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.berh.2026.102203_bib15","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1056\/NEJMoa0809493","article-title":"Denosumab for prevention of fractures in postmenopausal women with osteoporosis","volume":"361","author":"Cummings","year":"2009","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.berh.2026.102203_bib16","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/S2213-8587(17)30138-9","article-title":"10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension","volume":"5","author":"Bone","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"2","key":"10.1016\/j.berh.2026.102203_bib17","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1002\/jbmr.3337","article-title":"Vertebral fractures after discontinuation of denosumab: a post hoc analysis of the randomized placebo-controlled FREEDOM trial and its extension","volume":"33","author":"Cummings","year":"2018","journal-title":"J Bone Miner Res"},{"issue":"11","key":"10.1016\/j.berh.2026.102203_bib18","doi-asserted-by":"crossref","first-page":"2112","DOI":"10.1002\/jbmr.4705","article-title":"Multiple vertebral fractures after denosumab discontinuation: FREEDOM and FREEDOM extension trials additional post hoc analyses","volume":"37","author":"Cosman","year":"2022","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.berh.2026.102203_bib19","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.bone.2017.08.003","article-title":"Discontinuation of denosumab therapy for osteoporosis: a systematic review and position statement by ECTS","volume":"105","author":"Tsourdi","year":"2017","journal-title":"Bone"},{"issue":"6","key":"10.1016\/j.berh.2026.102203_bib20","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1002\/jbmr.3110","article-title":"Clinical features of 24 patients with rebound-associated vertebral fractures after denosumab discontinuation: systematic review and additional cases","volume":"32","author":"Anastasilakis","year":"2017","journal-title":"J Bone Miner Res"},{"issue":"5","key":"10.1016\/j.berh.2026.102203_bib21","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1210\/jc.2019-00221","article-title":"Pharmacological management of osteoporosis in postmenopausal women: an endocrine society* clinical practice guideline","volume":"104","author":"Eastell","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"10.1016\/j.berh.2026.102203_bib22","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/jbmr.1998","article-title":"Atypical subtrochanteric and diaphyseal femoral fractures: second report of a task force of the American society for bone and mineral research","volume":"29","author":"Shane","year":"2014","journal-title":"J Bone Miner Res"},{"issue":"3","key":"10.1016\/j.berh.2026.102203_bib23","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1210\/clinem\/dgaa048","article-title":"Pharmacological management of osteoporosis in postmenopausal women: an endocrine society guideline update","volume":"105","author":"Shoback","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"issue":"Suppl 1","key":"10.1016\/j.berh.2026.102203_bib24","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4158\/GL-2020-0524SUPPL","article-title":"AMERICAN association of clinical endocrinologists\/AMERICAN COLLEGE OF endocrinology clinical practice guidelines for the diagnosis and treatment of postmenopausal OSTEOPOROSIS-2020 update","volume":"26","author":"Camacho","year":"2020","journal-title":"Endocr Pract"},{"issue":"11","key":"10.1016\/j.berh.2026.102203_bib25","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1002\/jbmr.2892","article-title":"Identification of senescent cells in the bone microenvironment","volume":"31","author":"Farr","year":"2016","journal-title":"J Bone Miner Res"},{"issue":"9","key":"10.1016\/j.berh.2026.102203_bib26","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1038\/nm.4385","article-title":"Targeting cellular senescence prevents age-related bone loss in mice","volume":"23","author":"Farr","year":"2017","journal-title":"Nat Med"},{"issue":"3","key":"10.1016\/j.berh.2026.102203_bib27","doi-asserted-by":"crossref","DOI":"10.1172\/JCI154888","article-title":"Cellular senescence and the skeleton: pathophysiology and therapeutic implications","volume":"132","author":"Khosla","year":"2022","journal-title":"J Clin Investig"},{"issue":"4","key":"10.1016\/j.berh.2026.102203_bib28","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1210\/jc.2017-02694","article-title":"Inhibiting cellular senescence: a new therapeutic paradigm for age-related osteoporosis","volume":"103","author":"Khosla","year":"2018","journal-title":"J Clin Endocrinol Metab"},{"issue":"9","key":"10.1016\/j.berh.2026.102203_bib29","doi-asserted-by":"crossref","first-page":"2605","DOI":"10.1038\/s41591-024-03096-2","article-title":"Effects of intermittent senolytic therapy on bone metabolism in postmenopausal women: a phase 2 randomized controlled trial","volume":"30","author":"Farr","year":"2024","journal-title":"Nat Med"},{"issue":"9","key":"10.1016\/j.berh.2026.102203_bib30","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.135236","article-title":"Accelerated osteocyte senescence and skeletal fragility in mice with type 2 diabetes","volume":"5","author":"Eckhardt","year":"2020","journal-title":"JCI Insight"},{"issue":"19","key":"10.1016\/j.berh.2026.102203_bib31","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1056\/NEJM200105103441904","article-title":"Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis","volume":"344","author":"Neer","year":"2001","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.berh.2026.102203_bib32","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1359\/jbmr.2003.18.1.9","article-title":"The effect of teriparatide [human parathyroid hormone (1-34)] therapy on bone density in men with osteoporosis","volume":"18","author":"Orwoll","year":"2003","journal-title":"J Bone Miner Res"},{"issue":"20","key":"10.1016\/j.berh.2026.102203_bib33","doi-asserted-by":"crossref","first-page":"2028","DOI":"10.1056\/NEJMoa071408","article-title":"Teriparatide or alendronate in glucocorticoid-induced osteoporosis","volume":"357","author":"Saag","year":"2007","journal-title":"N Engl J Med"},{"issue":"10117","key":"10.1016\/j.berh.2026.102203_bib34","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/S0140-6736(17)32137-2","article-title":"Effects of teriparatide and risedronate on new fractures in post-menopausal women with severe osteoporosis (VERO): a multicentre, double-blind, double-dummy, randomised controlled trial","volume":"391","author":"Kendler","year":"2018","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.berh.2026.102203_bib35","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1001\/jama.2016.11136","article-title":"Effect of abaloparatide vs placebo on new vertebral fractures in postmenopausal women with osteoporosis: a randomized clinical trial","volume":"316","author":"Miller","year":"2016","journal-title":"JAMA"},{"issue":"8","key":"10.1016\/j.berh.2026.102203_bib36","doi-asserted-by":"crossref","first-page":"2949","DOI":"10.1210\/jc.2018-00163","article-title":"ACTIVExtend: 24 months of alendronate after 18 months of abaloparatide or placebo for postmenopausal osteoporosis","volume":"103","author":"Bone","year":"2018","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"10.1016\/j.berh.2026.102203_bib37","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1002\/jbmr.3051","article-title":"Treatment sequence matters: anabolic and antiresorptive therapy for osteoporosis","volume":"32","author":"Cosman","year":"2017","journal-title":"J Bone Miner Res"},{"issue":"5","key":"10.1016\/j.berh.2026.102203_bib38","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1210\/jc.2013-4440","article-title":"Two years of denosumab and teriparatide administration in postmenopausal women with osteoporosis (The DATA Extension study): a randomized controlled trial","volume":"99","author":"Leder","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"issue":"9999","key":"10.1016\/j.berh.2026.102203_bib39","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/S0140-6736(15)61120-5","article-title":"Denosumab and teriparatide transitions in postmenopausal osteoporosis (the DATA-switch study): extension of a randomised controlled trial","volume":"386","author":"Leder","year":"2015","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.berh.2026.102203_bib40","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1093\/hmg\/10.5.537","article-title":"Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST)","volume":"10","author":"Balemans","year":"2001","journal-title":"Hum Mol Genet"},{"issue":"3","key":"10.1016\/j.berh.2026.102203_bib41","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1086\/318811","article-title":"Bone dysplasia sclerosteosis results from loss of the SOST gene product, a novel cystine knot-containing protein","volume":"68","author":"Brunkow","year":"2001","journal-title":"Am J Hum Genet"},{"issue":"4","key":"10.1016\/j.berh.2026.102203_bib42","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/S0092-8674(01)00571-2","article-title":"LDL receptor-related protein 5 (LRP5) affects bone accrual and eye development","volume":"107","author":"Gong","year":"2001","journal-title":"Cell"},{"issue":"20","key":"10.1016\/j.berh.2026.102203_bib43","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1056\/NEJMoa013444","article-title":"High bone density due to a mutation in LDL-receptor-related protein 5","volume":"346","author":"Boyden","year":"2002","journal-title":"N Engl J Med"},{"issue":"23","key":"10.1016\/j.berh.2026.102203_bib44","doi-asserted-by":"crossref","first-page":"6267","DOI":"10.1093\/emboj\/cdg599","article-title":"Osteocyte control of bone formation via sclerostin, a novel BMP antagonist","volume":"22","author":"Winkler","year":"2003","journal-title":"EMBO J"},{"issue":"6","key":"10.1016\/j.berh.2026.102203_bib45","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1084\/jem.20031454","article-title":"Sclerostin is an osteocyte-expressed negative regulator of bone formation, but not a classical BMP antagonist","volume":"199","author":"van Bezooijen","year":"2004","journal-title":"J Exp Med"},{"issue":"20","key":"10.1016\/j.berh.2026.102203_bib46","doi-asserted-by":"crossref","first-page":"19883","DOI":"10.1074\/jbc.M413274200","article-title":"Sclerostin binds to LRP5\/6 and antagonizes canonical Wnt signaling","volume":"280","author":"Li","year":"2005","journal-title":"J Biol Chem"},{"issue":"29","key":"10.1016\/j.berh.2026.102203_bib47","doi-asserted-by":"crossref","first-page":"26770","DOI":"10.1074\/jbc.M504308200","article-title":"SOST is a ligand for LRP5\/LRP6 and a Wnt signaling inhibitor","volume":"280","author":"Sem\u00ebnov","year":"2005","journal-title":"J Biol Chem"},{"issue":"9","key":"10.1016\/j.berh.2026.102203_bib48","doi-asserted-by":"crossref","first-page":"5866","DOI":"10.1074\/jbc.M705092200","article-title":"Mechanical stimulation of bone in vivo reduces osteocyte expression of Sost\/sclerostin","volume":"283","author":"Robling","year":"2008","journal-title":"J Biol Chem"},{"issue":"4","key":"10.1016\/j.berh.2026.102203_bib49","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1359\/jbmr.081206","article-title":"Sclerostin antibody treatment increases bone formation, bone mass, and bone strength in a rat model of postmenopausal osteoporosis","volume":"24","author":"Li","year":"2009","journal-title":"J Bone Miner Res"},{"issue":"2","key":"10.1016\/j.berh.2026.102203_bib50","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1002\/jcph.239","article-title":"Multiple doses of sclerostin antibody romosozumab in healthy men and postmenopausal women with low bone mass: a randomized, double-blind, placebo-controlled study","volume":"54","author":"Padhi","year":"2014","journal-title":"J Clin Pharmacol"},{"issue":"5","key":"10.1016\/j.berh.2026.102203_bib51","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1056\/NEJMoa1305224","article-title":"Romosozumab in postmenopausal women with low bone mineral density","volume":"370","author":"McClung","year":"2014","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.berh.2026.102203_bib52","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1002\/jbmr.3735","article-title":"Bone-forming and antiresorptive effects of romosozumab in postmenopausal women with osteoporosis: bone histomorphometry and microcomputed tomography analysis after 2 and 12 months of treatment","volume":"34","author":"Chavassieux","year":"2019","journal-title":"J Bone Miner Res"},{"issue":"1","key":"10.1016\/j.berh.2026.102203_bib53","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1002\/jbmr.4457","article-title":"Modeling-based bone formation after 2 months of romosozumab treatment: results from the FRAME clinical trial","volume":"37","author":"Eriksen","year":"2022","journal-title":"J Bone Miner Res"},{"issue":"16","key":"10.1016\/j.berh.2026.102203_bib54","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1056\/NEJMoa1607948","article-title":"Romosozumab treatment in postmenopausal women with osteoporosis","volume":"375","author":"Cosman","year":"2016","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.berh.2026.102203_bib55","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1002\/jbmr.3622","article-title":"One year of romosozumab followed by two years of denosumab maintains fracture risk reductions: results of the FRAME extension study","volume":"34","author":"Lewiecki","year":"2019","journal-title":"J Bone Miner Res"},{"issue":"15","key":"10.1016\/j.berh.2026.102203_bib56","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1056\/NEJMoa1708322","article-title":"Romosozumab or alendronate for fracture prevention in women with osteoporosis","volume":"377","author":"Saag","year":"2017","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.berh.2026.102203_bib57","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1007\/s00198-024-07049-w","article-title":"Romosozumab in patients who experienced an on-study fracture: post hoc analyses of the FRAME and ARCH phase 3 trials","volume":"35","author":"Lane","year":"2024","journal-title":"Osteoporos Int"},{"issue":"10102","key":"10.1016\/j.berh.2026.102203_bib58","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1016\/S0140-6736(17)31613-6","article-title":"Romosozumab (sclerostin monoclonal antibody) versus teriparatide in postmenopausal women with osteoporosis transitioning from oral bisphosphonate therapy: a randomised, open-label, phase 3 trial","volume":"390","author":"Langdahl","year":"2017","journal-title":"Lancet"},{"issue":"37","key":"10.1016\/j.berh.2026.102203_bib59","doi-asserted-by":"crossref","first-page":"27285","DOI":"10.1074\/jbc.M702810200","article-title":"Skeletal involution by age-associated oxidative stress and its acceleration by loss of sex steroids","volume":"282","author":"Almeida","year":"2007","journal-title":"J Biol Chem"},{"issue":"7","key":"10.1016\/j.berh.2026.102203_bib60","doi-asserted-by":"crossref","DOI":"10.1172\/JCI195772","article-title":"Aged murine bone marrow myeloid and mesenchymal cells develop unique senescence phenotypes","volume":"136","author":"Doolittle","year":"2026","journal-title":"J Clin Investig"},{"issue":"7","key":"10.1016\/j.berh.2026.102203_bib61","doi-asserted-by":"crossref","DOI":"10.1172\/JCI204645","article-title":"Deconstructing senescence phenotypes in cells of the bone and bone marrow","volume":"136","author":"Hofbauer","year":"2026","journal-title":"J Clin Investig"},{"key":"10.1016\/j.berh.2026.102203_bib62","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.bone.2015.07.027","article-title":"Determinants of bone strength and quality in diabetes mellitus in humans","volume":"82","author":"Farr","year":"2016","journal-title":"Bone"},{"issue":"2","key":"10.1016\/j.berh.2026.102203_bib63","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/S2213-8587(15)00283-1","article-title":"Type 2 diabetes and the skeleton: new insights into sweet bones","volume":"4","author":"Shanbhogue","year":"2016","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"2","key":"10.1016\/j.berh.2026.102203_bib64","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1111\/joim.12725","article-title":"Type 2 diabetes mellitus and bone","volume":"283","author":"Compston","year":"2018","journal-title":"J Intern Med"},{"issue":"4","key":"10.1016\/j.berh.2026.102203_bib65","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1038\/nrendo.2016.153","article-title":"Mechanisms of diabetes mellitus-induced bone fragility","volume":"13","author":"Napoli","year":"2017","journal-title":"Nat Rev Endocrinol"},{"issue":"1","key":"10.1016\/j.berh.2026.102203_bib66","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1210\/jcem.86.1.7139","article-title":"Older women with diabetes have an increased risk of fracture: a prospective study","volume":"86","author":"Schwartz","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"10.1016\/j.berh.2026.102203_bib67","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1007\/s00198-006-0253-4","article-title":"Discrepancies in bone mineral density and fracture risk in patients with type 1 and type 2 diabetes--a meta-analysis","volume":"18","author":"Vestergaard","year":"2007","journal-title":"Osteoporos Int"},{"issue":"8","key":"10.1016\/j.berh.2026.102203_bib68","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.25106","article-title":"Type 2 diabetes and fracture risk in older women","volume":"7","author":"Zoulakis","year":"2024","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.berh.2026.102203_bib69","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/0014-4827(61)90192-6","article-title":"The serial cultivation of human diploid cell strains","volume":"25","author":"Hayflick","year":"1961","journal-title":"Exp Cell Res"},{"issue":"4","key":"10.1016\/j.berh.2026.102203_bib70","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/j.cell.2019.10.005","article-title":"Cellular senescence: defining a path forward","volume":"179","author":"Gorgoulis","year":"2019","journal-title":"Cell"},{"issue":"15","key":"10.1016\/j.berh.2026.102203_bib71","doi-asserted-by":"crossref","DOI":"10.1172\/JCI158450","article-title":"Cellular senescence: a key therapeutic target in aging and diseases","volume":"132","author":"Zhang","year":"2022","journal-title":"J Clin Investig"},{"key":"10.1016\/j.berh.2026.102203_bib72","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1146\/annurev-physiol-030212-183653","article-title":"Aging, cellular senescence, and cancer","volume":"75","author":"Campisi","year":"2013","journal-title":"Annu Rev Physiol"},{"issue":"12","key":"10.1016\/j.berh.2026.102203_bib73","doi-asserted-by":"crossref","first-page":"2853","DOI":"10.1371\/journal.pbio.0060301","article-title":"Senescence-associated secretory phenotypes reveal cell-nonautonomous functions of oncogenic RAS and the p53 tumor suppressor","volume":"6","author":"Copp\u00e9","year":"2008","journal-title":"PLoS Biol"},{"issue":"8","key":"10.1016\/j.berh.2026.102203_bib74","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1038\/ncb1909","article-title":"Persistent DNA damage signalling triggers senescence-associated inflammatory cytokine secretion","volume":"11","author":"Rodier","year":"2009","journal-title":"Nat Cell Biol"},{"issue":"2","key":"10.1016\/j.berh.2026.102203_bib75","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.cell.2022.11.001","article-title":"Hallmarks of aging: an expanding universe","volume":"186","author":"L\u00f3pez-Ot\u00edn","year":"2023","journal-title":"Cell"},{"issue":"3","key":"10.1016\/j.berh.2026.102203_bib76","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1172\/JCI64098","article-title":"Cellular senescence and the senescent secretory phenotype: therapeutic opportunities","volume":"123","author":"Tchkonia","year":"2013","journal-title":"J Clin Investig"},{"key":"10.1016\/j.berh.2026.102203_bib77","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.bone.2019.01.015","article-title":"Cellular senescence in bone","volume":"121","author":"Farr","year":"2019","journal-title":"Bone"},{"issue":"5","key":"10.1016\/j.berh.2026.102203_bib78","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1038\/s41574-020-0335-y","article-title":"The role of cellular senescence in ageing and endocrine disease","volume":"16","author":"Khosla","year":"2020","journal-title":"Nat Rev Endocrinol"},{"key":"10.1016\/j.berh.2026.102203_bib79","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1146\/annurev-physiol-021119-034332","article-title":"The osteocyte: new insights","volume":"82","author":"Robling","year":"2020","journal-title":"Annu Rev Physiol"},{"issue":"8","key":"10.1016\/j.berh.2026.102203_bib80","doi-asserted-by":"crossref","DOI":"10.1172\/JCI162519","article-title":"Local senolysis in aged mice only partially replicates the benefits of systemic senolysis","volume":"133","author":"Farr","year":"2023","journal-title":"J Clin Investig"},{"issue":"12","key":"10.1016\/j.berh.2026.102203_bib81","doi-asserted-by":"crossref","DOI":"10.1172\/JCI179834","article-title":"Osteochondroprogenitor cells and neutrophils expressing p21 and senescence markers modulate fracture repair","volume":"134","author":"Saul","year":"2024","journal-title":"J Clin Investig"},{"issue":"5","key":"10.1016\/j.berh.2026.102203_bib82","doi-asserted-by":"crossref","DOI":"10.1111\/acel.13602","article-title":"Targeted clearance of p21- but not p16-positive senescent cells prevents radiation-induced osteoporosis and increased marrow adiposity","volume":"21","author":"Chandra","year":"2022","journal-title":"Aging Cell"},{"issue":"6","key":"10.1016\/j.berh.2026.102203_bib83","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1002\/jbmr.3978","article-title":"Targeted reduction of senescent cell burden alleviates focal radiotherapy-related bone loss","volume":"35","author":"Chandra","year":"2020","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.berh.2026.102203_bib84","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/j.ebiom.2019.08.069","article-title":"Senolytics decrease senescent cells in humans: preliminary report from a clinical trial of Dasatinib plus quercetin in individuals with diabetic kidney disease","volume":"47","author":"Hickson","year":"2019","journal-title":"EBioMedicine"},{"key":"10.1016\/j.berh.2026.102203_bib85","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1016\/j.ebiom.2018.12.052","article-title":"Senolytics in idiopathic pulmonary fibrosis: results from a first-in-human, open-label, pilot study","volume":"40","author":"Justice","year":"2019","journal-title":"EBioMedicine"},{"issue":"5","key":"10.1016\/j.berh.2026.102203_bib86","doi-asserted-by":"crossref","DOI":"10.1111\/acel.14489","article-title":"Characterization of human senescent cell biomarkers for clinical trials","volume":"24","author":"Farr","year":"2025","journal-title":"Aging Cell"},{"issue":"5","key":"10.1016\/j.berh.2026.102203_bib87","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1111\/joim.13141","article-title":"Senolytic drugs: from discovery to translation","volume":"288","author":"Kirkland","year":"2020","journal-title":"J Intern Med"},{"issue":"8","key":"10.1016\/j.berh.2026.102203_bib88","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1038\/s41591-018-0092-9","article-title":"Senolytics improve physical function and increase lifespan in old age","volume":"24","author":"Xu","year":"2018","journal-title":"Nat Med"},{"issue":"4","key":"10.1016\/j.berh.2026.102203_bib89","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1007\/s00198-007-0543-5","article-title":"FRAX and the assessment of fracture probability in men and women from the UK","volume":"19","author":"Kanis","year":"2008","journal-title":"Osteoporos Int"},{"issue":"11","key":"10.1016\/j.berh.2026.102203_bib90","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1016\/j.tem.2012.03.008","article-title":"Estrogen and the skeleton","volume":"23","author":"Khosla","year":"2012","journal-title":"Trends Endocrinol Metabol"},{"issue":"3","key":"10.1016\/j.berh.2026.102203_bib91","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1002\/jbmr.262","article-title":"The unitary model for estrogen deficiency and the pathogenesis of osteoporosis: is a revision needed?","volume":"26","author":"Khosla","year":"2011","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.berh.2026.102203_bib92","series-title":"EVENITY (romosozumab-aqqg) injection, for subcutaneous use: prescribing information","year":"2019"},{"issue":"2","key":"10.1016\/j.berh.2026.102203_bib93","first-page":"195","article-title":"Romosozumab versus alendronate and fracture risk in women with osteoporosis","volume":"378","author":"Saag","year":"2018","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.berh.2026.102203_bib94","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1111\/acel.12344","article-title":"The Achilles' heel of senescent cells: from transcriptome to senolytic drugs","volume":"14","author":"Zhu","year":"2015","journal-title":"Aging Cell"}],"container-title":["Best Practice & Research Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521694226000884?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521694226000884?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T08:59:55Z","timestamp":1791017995000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521694226000884"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":94,"alternative-id":["S1521694226000884"],"URL":"https:\/\/doi.org\/10.1016\/j.berh.2026.102203","relation":{},"ISSN":["1521-6942"],"issn-type":[{"value":"1521-6942","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Future directions of osteoanabolic therapies in osteoporosis: Integrating current anabolic agents and emerging senescence-targeted strategies","name":"articletitle","label":"Article Title"},{"value":"Best Practice & Research Clinical Rheumatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.berh.2026.102203","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"102203"}}